Tsim kev kho ua ke ntawm SHP2 inhibitor BBP-398 thiab Opdivo!

BridgeBio Pharmaceuticals tsis ntev los no tshaj tawm qhov tsis suav nrog, koom nrog pab nyiaj kho mob koom tes nrog Bristol-Myers Squibb (BMS) los tshuaj xyuas qhov muaj peev xwm zoo tshaj plaws hauv chav kawm SHP2 inhibitor BBP-398 thiab tiv thaiv PD-1 kev kho Opdivo (Lub Npe Lub Npe: nivolumab) ua ke kev kho mob, siv los kho cov neeg mob uas muaj cov qog ua haujlwm zoo nrog KRAS hloov pauv, vam tias yuav muab txoj kev kho mob zoo rau cov neeg mob uas nyuaj rau kho mob qog noj ntshav.

Kev koom tes no tseem yuav suav nrog kev pib ua ntu 1/2 los tshuaj xyuas BBP-398 {{4}} Opdivo ua ob txoj kev kho mob thiab BBP-398+Opdivo+KRASG12C inhibitor ua kev kho mob peb zaug, ua thawj kab thiab thib ob -kab kev kho mob xaiv rau kev kho mob ntawm kev hloov pauv KRAS Kev nyab xeeb thiab kev ua tau zoo ua ntej ntawm cov mob qog noj ntshav uas tsis yog me me (NSCLC). Raws li cov ntsiab lus tshwj xeeb ntawm kev koom tes, BridgeBio yuav txhawb nqa kev tshawb fawb thiab Bristol-Myers Squibb yuav muab Opdivo. BridgeBio thiab Bristol-Myers Squibb yuav koom ua ke them tus nqi ntawm cov haujlwm kho mob rau kev sib koom tes.

BBP-398 tau tsim los koom tes nrog Kev Kho Mob Tshawb Fawb Lub Tsev Haujlwm ntawm University of Texas MD Anderson Cancer Center. Nws yog hom tshiab ntawm SHP2 inhibitor, feem ntau yog siv los kho cov qog nqaij hlav tsis haum tshuaj thiab lwm cov qog nqaij tawv. Thaum Lub Yim Hli 2020, BridgeBio thiab LianBio tau mus txog qhov kev koom tes zoo los kawm BBP-398 thiab LianBio hauv ntau yam qog nqaij hlav (xws li tsis mob qog noj ntshav ntawm tes, mob qog noj ntshav thiab mob qog noj ntshav) hauv Suav teb thiab lwm qhov lag luam loj hauv Asia. Kev kho ua ke nrog lwm cov tshuaj.

Tam sim no, BridgeBio tab tom nce qib 1 kev sim tshuaj kho mob ntawm BBP-398 rau cov neeg mob uas muaj cov qog nqaij hlav uas tau tsav los ntawm kev hloov pauv hauv MAPK cov cim qhia kev (suav nrog RAS thiab receptor tyrosine kinase noob).

Cov qauv tshuaj lom neeg ntawm BBP-398 (daim duab qhov chaw: selleckchem.com)

SHP2 yog cov protein tyrosine phosphatase, uas txuas qhov kev loj hlob zoo, cytokine thiab cov cim sib txuas nrog cov nqes nqes hav RAS/ERK-MAPK txoj hauv kev los tswj cov cell loj hlob thiab muaj sia nyob. Kev ua haujlwm ntau dhau ntawm SHP2 txoj hauv kev feem ntau yog tsav los ntawm kev hloov pauv noob. Nws yog qhov tseem ceeb hauv ntau yam mob qog noj ntshav thiab tiv thaiv txheej txheem rau ntau yam kev kho mob.

Kev hloov pauv KRAS tshwm sim kwv yees li 27% ntawm NSCLC cov xwm txheej thiab kwv yees li 17% ntawm cov qog nqaij hlav tsis zoo. Kev tiv thaiv-PD-1 kev kho mob ua ke nrog BBP-398 thiab lwm yam kev kho mob tau cog lus tseg rau cov neeg mob uas muaj kev hloov pauv KRAS.

Dr. Frank McCormick, Tus Thawj Coj ntawm BridgeBio Oncology, tau hais tias:" Cov qog nqaij hlav uas tau tsav los ntawm MAPK kev ua haujlwm ntau dhau, suav nrog qee yam RAS hloov pauv, xws li KRASG12C, tuaj yeem ua rau SHP2 inhibition. Los ntawm kev sib koom tes no, peb vam tias yuav piav qhia meej txog peb li SHP2 Inhibitors txhim kho lub peev xwm ntawm kev tiv thaiv kab mob qog noj ntshav thiab lwm yam kev kho mob, yog li txhawm rau muab kev kho mob sai thiab nyab xeeb raws li ua tau rau cov neeg mob nyuaj kho mob."

Emma Lees, Tus Lwm Thawj Coj ntawm Kev Tshawb Fawb Cancer, Bristol-Myers Squibb, hais tias:" Peb thawj qhov tseem ceeb yog txhawm rau tsim cov tshuaj tshiab tsom mus rau cov txheej txheem sab hauv ntawm cov qog (suav nrog txoj kev MAPK). Peb tos ntsoov yuav pib tshawb fawb soj ntsuam ua ke nrog MAPK txoj hauv kev tiv thaiv thiab PD-1 thaiv. Cov txheej txheem ntawm kev tshem tawm tau txais txiaj ntsig zoo rau kev kho mob ntawm KRAS hloov pauv NSCLC."